Sixty-nine depressive patients (DSM III criteria: 296.2, 296.3, 296.5, 300.4) were treated with 40 to 60 mg citalopram (CIT) daily for 4 weeks. Among them, 45 responded to treatment (improvement > 50% on the 21-item Hamilton Rating Scale for Depression [HAM-D]) and continued their treatment for another week before being released from the study. The 24 nonresponders were randomized and comedicated under double-blind conditions with lithium carbonate (Li) (2 x 400 mg/day) (CIT-Li group) or with placebo (CIT-Pl group) from days 29 to 35. For days 36 to 42, the patients of both subgroups were treated openly with Li (800 mg/day) in addition to the ongoing CIT treatment. On day 35, 6 of 10 patients responded to the CIT-Li combination, whereas ...
Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipol...
There is compelling evidence from placebo-controlled studies that lithium augmentation is an effecti...
Approximately 30-45% of patients with major depressive episode (MDE) do not fully respond to standar...
Citalopram, a new bicyclic antidepressant, is the most selective serotonin reuptake inhibitor. In a ...
The therapeutic efficacy of lithium added to tricyclic antidepressants (TCA) or related thymoleptics...
The effect of comedication with fluvoxamine on the plasma concentrations of the enantiomers of cital...
Authors compared plasma concentrations of citalopram (CIT) enantiomers and their metabolites in pati...
Reviews current literature on lithium augmentation (LA) in patients not responding to selective sero...
Results of randomized, placebo-controlled trials with the selective serotonin reuptake inhibitor cit...
Background: Lithium augmentation of antidepressants for treatment of unipolar major depression was o...
Background: The late onset of therapeutic response and a relatively large proportion of nonresponder...
BACKGROUND: Lithium augmentation of antidepressants for treatment of unipolar major depression was o...
Citalopram is a chiral antidepressant drug. Its eutomer, S-citalopram (escitalopram), has recently b...
目的:观察西酞普兰治疗抑郁障碍的疗效和安全性.方法:采用多中心开放试验,纳入29例单相抑郁或双相障碍抑郁发作患者.西酞普兰非固定剂量治疗6周.汉密尔顿抑郁量表(HAMD)评定疗效,治疗时出现的症状量表...
From data collected during routine TDM, plasma concentrations of citalopram (CIT) and its metabolite...
Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipol...
There is compelling evidence from placebo-controlled studies that lithium augmentation is an effecti...
Approximately 30-45% of patients with major depressive episode (MDE) do not fully respond to standar...
Citalopram, a new bicyclic antidepressant, is the most selective serotonin reuptake inhibitor. In a ...
The therapeutic efficacy of lithium added to tricyclic antidepressants (TCA) or related thymoleptics...
The effect of comedication with fluvoxamine on the plasma concentrations of the enantiomers of cital...
Authors compared plasma concentrations of citalopram (CIT) enantiomers and their metabolites in pati...
Reviews current literature on lithium augmentation (LA) in patients not responding to selective sero...
Results of randomized, placebo-controlled trials with the selective serotonin reuptake inhibitor cit...
Background: Lithium augmentation of antidepressants for treatment of unipolar major depression was o...
Background: The late onset of therapeutic response and a relatively large proportion of nonresponder...
BACKGROUND: Lithium augmentation of antidepressants for treatment of unipolar major depression was o...
Citalopram is a chiral antidepressant drug. Its eutomer, S-citalopram (escitalopram), has recently b...
目的:观察西酞普兰治疗抑郁障碍的疗效和安全性.方法:采用多中心开放试验,纳入29例单相抑郁或双相障碍抑郁发作患者.西酞普兰非固定剂量治疗6周.汉密尔顿抑郁量表(HAMD)评定疗效,治疗时出现的症状量表...
From data collected during routine TDM, plasma concentrations of citalopram (CIT) and its metabolite...
Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipol...
There is compelling evidence from placebo-controlled studies that lithium augmentation is an effecti...
Approximately 30-45% of patients with major depressive episode (MDE) do not fully respond to standar...